# Contents

1 Cancer Overdiagnosis and Overtreatment .......................... 1  
   Laurence Klotz

2 Can We Screen and Still Reduce Overdiagnosis? ................. 9  
   Peter Ka-Fung Chiu and Monique J. Roobol

3 The Role of Fear in Overdiagnosis and Overtreatment ........... 21  
   Iona Heath

4 Ethical and Legal Considerations in Active Surveillance for Prostate Cancer ................................................. 31  
   Lionne D.F. Venderbos

5 Gleason 6 Tumors Should Still Be Labeled as Cancer .......... 41  
   Angelo M. De Marzo and Jonathan I. Epstein

6 Risk-Based Selection for Active Surveillance ...................... 53  
   Jan F.M. Verbeek, Monique J. Roobol,  
   and Ewout W. Steyerberg

7 Surveillance at the Margins: Management of High-Volume Gleason 6, PSA > 10, or Gleason 3 + 4 .......................... 65  
   Laurence Klotz

8 How Should Patients on Active Surveillance Be Followed? .... 71  
   Frank-Jan H. Drost, Monique J. Roobol,  
   and Leonard P. Bokhorst

9 Triggers for Intervention ............................................. 83  
   Tuomas Mirtti, Hanna Vasarainen, and Antti Rannikko

10 MR Imaging in Prostate Tumor Volume Assessment:  
    How Accurate? .................................................. 95  
    Ivo G. Schoots and Theo H. van der Kwast

11 Can MRI Replace Biopsy in Men on Surveillance? ............ 111  
   Francesco Giganti, Vasilis Stavrinides,  
   and Caroline M. Moore

12 Tissue-Based Markers for Risk Prediction ....................... 121  
   Chad A. Reichard and Eric A. Klein
13 International AS Registry: The Movember
Foundation’s Global Action Plan Prostate Cancer
Active Surveillance Initiative ....................................... 135
Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen,
Liying Zhang, Rachelle Kirk-Burnnand, Sam Gledhill,
and Mark Buzza

14 Better-Informed Decision-Making
to Optimize Patient Selection ..................................... 149
Lara Bellardita, Paola Dordoni, Letizia De Luca,
Julia Paola Menichetti Delor, and Riccardo Valdagni

15 How Does QoL Compare Between Surveillance
and Active Treatment? .............................................. 169
Lionne D.F. Venderbos, Stephanie D. Brandhof,
and Ida J. Korfage

16 The Potential Benefits of Diet and Physical Activity
Among Active Surveillance Patients with Low-Burden
Prostate Cancer .......................................................... 183
Stacey A. Kenfield, David Tat, and June M. Chan

17 Is There a Role for Pharmacologic Manipulation
to Prevent Progression in Men on Active Surveillance?
The Role of 5-ARIs, Statins, and Metformin .................. 199
Roy Mano and David Margel

18 The Update of Active Surveillance Around the World:
Utilization and Outcomes ........................................... 207
Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor,
and Stacy Loeb

19 Tissue Preservation: Active Surveillance
and Focal Therapy as Complimentary Strategies ........... 217
Juan Gómez Rivas and Mark Emberton

20 The Economics of Active Surveillance
for Prostate Cancer ................................................... 229
Robert B. Lurvey and Marc A. Dall’Era

21 Research Questions in Active Surveillance .................. 239
Laurence Klotz

Index ............................................................................. 243
Active Surveillance for Localized Prostate Cancer
A New Paradigm for Clinical Management
Klotz, L. (Ed.)
2018, XII, 250 p. 39 illus., 27 illus. in color., Hardcover
ISBN: 978-3-319-62709-0
A product of Humana Press